Does PDS Biotechnology Corporation (NASDAQ: PDSB) Offer Growth And Stability?

PDS Biotechnology Corporation (NASDAQ:PDSB) shares, rose in value on Thursday, April 04, with the stock price down by -3.94% to the previous day’s close as strong demand from buyers drove the stock to $3.54.

Actively observing the price movement in the recent trading, the stock is buoying the session at $3.68. The value of beta (5-year monthly) is 1.73. Referring to stock’s 52-week performance, its high was $10.27, and the low was $3.61. On the whole, PDSB has fluctuated by -39.05% over the past month.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


With the market capitalization of PDS Biotechnology Corporation currently standing at about $129.66 million, investors are eagerly awaiting this quarter’s results, scheduled for May 13, 2024 – May 17, 2024. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.37, which is expected to increase to -$0.28 for fiscal year -$1.48 and then to about -$1.61 by fiscal year 2025. Data indicates that the EPS growth is expected to be -6.50% in 2025, while the next year’s EPS growth is forecast to be -8.80%.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were no upward and no downward review(s) in last seven days. We see that PDSB’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 50% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of PDSB currently trading nearly -24.41% and -31.90% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 29.20, while the 7-day volatility ratio is showing 11.66% which for the 30-day chart, stands at 8.92%. Furthermore, PDS Biotechnology Corporation (PDSB)’s beta value is 1.72, and its average true range (ATR) is 0.39.

A comparison of PDS Biotechnology Corporation (PDSB) with its peers suggests the former has fared considerably weaker in the market. PDSB showed an intraday change of -3.94% in today’s session so far, and over the past year, it shrunk by -41.67%%.

Data on historical trading for PDS Biotechnology Corporation (NASDAQ:PDSB) indicates that the trading volumes over the past 10 days have averaged 1.6 million and over the past 3 months, they’ve averaged 902.31K. According to company’s latest data on outstanding shares, there are 36.68 million shares outstanding.

Nearly 4.89% of PDS Biotechnology Corporation’s shares belong to company insiders and institutional investors own 22.45% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 5.51 million shares as on Mar 15, 2024, resulting in a short ratio of 5.52. According to the data, the short interest in PDS Biotechnology Corporation (PDSB) stood at 17.70% of shares outstanding as of Mar 15, 2024; the number of short shares registered in Feb 15, 2024 reached 5.01 million. The stock has fallen by -28.87% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the PDSB stock heading into the next quarter.